5-Amino-1MQ

A 2009 study in the journal Metabolism showed that AMPK activation (downstream of NAD+ restoration via 5-Amino-1MQ) increases fat oxidation by 340% while sparing muscle tissue. Higher NAD+ also suppresses mTOR when appropriate, shifting protein synthesis toward muscle building rather than fat storage.

5-Amino-1MQ is a mitochondrial complex 3 inhibitor that increases metabolic rate by ~25% through mitochondrial uncoupling, independent of activity level. Added only after 8 weeks of retatrutide with stable labs (thyroid normal, electrolytes normal, liver function normal, protein intake 1.5g/lb minimum, micronutrients perfect). Dose: 25mg subcutaneous daily (not oral). Combined triple stack: retatrutide (30-40% caloric deficit) + tesamorelin (muscle preservation) + 5-amino-1MQ (additional 20-25% metabolic increase) = 50-55% caloric deficit potential, producing 5-7 lbs fat loss per week with 95% fat composition.

A 2022 study in Obesity showed human subjects using 5-Amino-1MQ lost an average of 18.3 pounds of fat while gaining 4.2 pounds of lean muscle mass in 16 weeks without exercise. The compound also improves satellite cell activation (muscle stem cells) through sirtuin activity.

A 2023 Diabetes Care study showed human subjects with type 2 diabetes using 5-Amino-1MQ achieved HbA1c reduction of 1.4 percentage points over 12 weeks (3 months), enough to move from diabetic to pre-diabetic range. This occurs because NAD+ restoration brings beta cell mitochondria back online for proper insulin production.

A 2022 study in Cell Metabolism showed 5-Amino-1MQ improved HOMA-IR scores (clinical measure of insulin resistance) by 34% in just 8 weeks in human subjects.

A 2023 study in the FEB Journal showed that NAD+ restoration (via NNMT inhibition by 5-Amino-1MQ) improved insulin sensitivity by 41% in pre-diabetic subjects.

A 2022 study in the Journal of Obesity showed human subjects using 5-Amino-1MQ lost 8.2 pounds of fat while gaining 2.1 pounds of muscle in 12 weeks without changing their diet or exercising.

A 2021 study published in the journal Nutrients demonstrated that 5-Amino-1MQ supplementation increased mitochondrial respiration by 34% in human subjects, not animal models.

A 2023 study by Konopleski and Alowski in Nutrients directly compared protocols. Retatrutide + 5-amino-1MQ + tesamorelin produced 24% weight loss with only 1.5 lbs muscle loss per 20 lbs fat. Metabolic rate was maintained or increased ~4-5%. Pancreatic beta cell mass preserved. Hypothalamic GLP-1 receptor downregulation minimal. Mitochondrial function enhanced and protected. Post-discontinuation weight regain was 35% at most in 12 months (vs 60% in 6 months with stacking). Insulin sensitivity, lipid profiles, and inflammatory markers all improved.

5-Amino-1MQ inhibits NNMT (NAD+ consuming enzymes), increasing cellular NAD+ levels. A 2022 study by Kanto in Nature showed 5-amino-1MQ administration increases NAD+ levels by 42%, SIRT1 and SIRT3 activation increases dramatically, mitochondrial ATP production increases by 34%, and mitochondrial reactive oxygen species production decreases by 28%. Higher NAD+ activates sirtuins which activate mitochondrial biogenesis, autophagy, and cellular repair.

A 2022 study in the Journal of Neuroscience showed restoring NAD+ in aged mice improved spatial memory by 67% and reversed cognitive decline. This also restores synaptic plasticity, allowing neurons to form new connections.

A 2021 study in Nature Aging showed SIRT1 activation (downstream of NAD+ restoration) increased neuronal autophagy by 340%, leading to clearance of pathological amyloid beta, the hallmark protein of Alzheimer's disease.

The speaker outlines a comprehensive five-tier stacking protocol designed for cellular energy optimization. Tier one is foundational supplements; tier two adds NAD+ (50–100 mg SC, 3–5x/week); tier three adds Epitalon (500 mcg–1 mg/day, 10–20 days) and FOXO4-DRI (2–5 mg EOD, 3 doses); tier four adds SS-31 (2 mg/day SC) and MOTS-c (10 mg/week, MWF); tier five conditionally adds Five Amino 1MQ (50–100 mg/day), methylene blue (5–10 mg/day), and injectable L-carnitine (200–500 mg, 3–5x/week). All peptide tiers are cycled eight to twelve weeks on and four to eight weeks off.

The speaker explicitly restricts the recommendation for Five Amino 1MQ to individuals with metabolic dysfunction specifically tied to excess body fat, implying it is not appropriate or necessary for metabolically healthy individuals. This represents a conditional contraindication based on metabolic status. The mechanism cited is enzyme inhibition preventing NAD+ precursor waste in adipose tissue.

The speaker issues a general safety and efficacy caveat that training, nutrition, and sleep must be established before any peptide or supplement protocol is layered on top. The explicit claim is that these protocols enhance existing work but cannot replace it. This functions as a contraindication-adjacent warning against using peptides as a substitute for foundational health behaviors.

The speaker explicitly frames the entire five-tier protocol as modular, meaning individuals do not need to implement all tiers simultaneously to observe results. Each tier is designed to build upon the previous, but partial adoption is presented as valid. This is a structural recommendation rather than a mechanistic or clinical claim.

The speaker explicitly flags 5-Amino-1MQ as a conditional compound not appropriate for general use, restricting its recommendation to individuals with metabolic dysfunction specifically linked to excess body fat. This represents a targeted contraindication within the protocol. The implied warning is that using it outside this context may not be warranted.

The speaker issues a clear advisory that training, nutrition, and sleep are non-negotiable prerequisites before any peptide or supplement protocol is initiated. Peptides are framed as enhancers of existing healthy behaviors, not replacements for them. This is presented as a foundational safety and efficacy principle throughout the protocol.

The speaker explicitly frames the entire protocol as modular, meaning users do not need to implement all tiers simultaneously to see results. Each tier builds on the previous but can be used in isolation. This is presented as a practical safety and accessibility consideration rather than a clinical recommendation.

5-Amino-1MQ is presented as a conditional tier-five addition specifically for individuals with metabolic dysfunction associated with excess body fat. The mechanism described is inhibition of an enzyme (NNMT) that wastes NAD+ precursors in adipose tissue. The recommended dose is 50–100 mg per day, and it is not recommended for individuals without this specific metabolic context.

Dr. Bachmeyer explicitly states that Retatrutide and 5-Amino-1MQ should be used simultaneously but NOT combined in the same vial — they are separate preparations used concurrently as a stack.

Dr. Bachmeyer references another doctor's finding that Alzheimer's patients are insanely low on glutathione and affirms this is correct, noting it as one of the first things to check. This is presented alongside the 5-Amino-1MQ/Retatrutide Alzheimer's protocol as complementary context.

When mitochondrial function is restored by 5-Amino-1MQ, reactive oxygen species (ROS) production drops. Dysfunctional mitochondria leak electrons like a faulty power plant, generating ROS that drives inflammation. The hierarchy is: less ROS → less inflammation → better insulin signaling. 5-Amino-1MQ fixes the root cause rather than masking the symptom.

Menopause is described as a metabolic collapse, not just estrogen decline. When estrogen drops, estrogen-dependent thermogenesis tanks and mitochondrial uncoupling protein UCP-1 activation decreases, causing mitochondria to become too efficient (less heat, lower metabolic rate, fat gain). Dr. Bachmeyer recommends the 5-Amino-1MQ + Retatrutide stack specifically for menopausal metabolic dysfunction.

When using both Retatrutide and 5-Amino-1MQ together, the combined data suggests 23% body fat reduction with 8% lean muscle mass gain in 24 weeks with minimal exercise. 5-Amino-1MQ drives muscle mitochondrial biogenesis and protein synthesis while Retatrutide reduces appetite, improves muscle insulin sensitivity, and prevents protein breakdown.

5-Amino-1MQ improves satellite cell activation — satellite cells are the stem cells that repair and build muscle tissue. Sirtuin activity (activated downstream of NAD+ restoration) directly improves satellite cell differentiation, enhancing muscle repair capacity.

AMPK activation from NAD+ restoration preferentially stimulates mTOR signaling in muscle cells while suppressing it in fat cells (selective mTOR activation). Combined with PGC1-alpha driving mitochondrial biogenesis specifically in myocytes, this allows simultaneous fat loss and muscle building — opposite of the typical pattern where both are lost together.

When combined for neurodegeneration, 5-Amino-1MQ restores the neuronal power plant (mitochondria produce ATP again) while Retatrutide provides the growth signal (BDNF tells brain to build new connections and clear old debris). Together they don't just stop cognitive decline — they reportedly reverse it.

5-Amino-1MQ crosses the blood-brain barrier (though not easily) and restores NAD+ in the brain. This activates sirtuins which activate FOXO3, a transcription factor that upregulates autophagy — the cellular recycling system. Neuronal autophagy clears accumulated amyloid and tau proteins that cause Alzheimer's disease.

When used together, 5-Amino-1MQ fixes the target of insulin (mitochondria/muscles can use glucose) while Retatrutide fixes the stimulus (body stops flooding itself with glucose and insulin). The demand drops, the capacity increases, and the insulin signaling system resets. This dual approach is more effective than either compound alone.

When mitochondria are dysfunctional, glucose accumulates as glucose-6-phosphate, gets shunted into lipid synthesis (stored fat), and excess lipid intermediates (diacylglycerol/DAG) activate PKC, which phosphorylates IRS-1 on the wrong amino acids, blocking insulin signaling. 5-Amino-1MQ fixes this by restoring mitochondrial oxidative capacity so glucose is properly oxidized rather than converted to DAG.

When NAD+ rises from NNMT inhibition, cells activate sirtuins (specifically SIRT3, longevity genes). Sirtuins activate PGC1-alpha, the master controller of mitochondrial biogenesis, prompting the body to build new mitochondria. High NAD+ also activates AMPK, the cellular energy sensor, which shifts metabolism from glucose dependence to fat oxidation.

5-Amino-1MQ is a small molecule metabolite that inhibits NNMT (nicotinamide N-methyltransferase), an enzyme that consumes NAD+. In obese, menopausal, diabetic, and neurologically declining individuals, NNMT is overactive, depleting NAD+. By blocking NNMT, NAD+ levels increase, restoring mitochondrial function and ATP production.

Dr. Bachmeyer recommends combining Retatrutide (top-down hormonal approach) with 5-Amino-1MQ (bottom-up mitochondrial approach) as a synergistic stack addressing the three fundamental biological failures: systemic inflammation, insulin resistance, and mitochondrial dysfunction. 5-Amino-1MQ fixes the cellular power plant while Retatrutide fixes hormonal signaling and appetite control. Together they attack metabolic disease from opposite directions.

Dr. Jones recommends that women over 50 should consider 5-amino (5-Amino-1MQ) for baseline NAD levels as part of a foundational protocol alongside a GLP-1 medication and bioidentical hormone replacement therapy. He positions it as a higher priority than tirzepatide or semaglutide for this demographic. No dosage specified.

Dr. Bachmeyer recommends retatrutide combined with 5-amino-1MQ and tesamorelin as an 'infinitely superior' alternative to stacking GLP-1s. This triple approach optimizes different biological systems simultaneously without creating contradictory signals. It respects receptor biology and metabolic adaptation by targeting distinct pathways: appetite/fat mobilization (retatrutide), cellular energy/mitochondrial health (5-amino-1MQ), and lean mass preservation/GH secretion (tesamorelin).